Warning Letter Record: originalc.co.uk (2026-10-02) — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
TL;DR
The short version: The FDA Center for Tobacco Products issued a warning letter to originalc.co.uk on October 2, 2026 (Reference RW2602440), finding that Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg was sold to a person under age 21 through the website, violating section 906(d)(5) of the FD&C Act, which prohibits tobacco product sales to individuals younger than 21. The letter requires a written response within 15 working days detailing corrective actions and compliance plans, warning that failure to comply may result in civil penalties, seizure, and/or injunction.
Argus analysis
# FDA Warning Letter: originalc.co.uk — Age Verification Failure in E-Liquid Sales
The FDA's Center for Tobacco Products issued a warning letter to originalc.co.uk on October 2, 2026, after determining that e-liquid products on the company's website were offered for sale to US consumers. During an FDA investigation, an underage individual successfully purchased Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg from the site. The agency classified this transaction as a violation of federal tobacco law, as the company failed to implement adequate age-verification controls at the point of sale.
The violation centers on section 906(d)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 387f(d)(5)), which establishes 21 years as the minimum purchase age for all tobacco products, including nicotine-containing e-liquids. Under section 903(a)(7)(B) (21 U.S.C. § 387c(a)(7)(B)), products sold to individuals under 21 are automatically misbranded. The warning references compliance obligations under 21 C.F.R. Parts 1140, 1141, and 1143, which govern tobacco product labeling, advertising, and retail sales requirements. These regulations require retailers to maintain systems preventing underage access, whether online or in-store.
The company has 15 working days from receipt to submit a written response detailing corrective actions, discontinuation dates for violative sales, and a compliance maintenance plan. Peer compliance officers in e-commerce tobacco retail should note that the FDA copied Shopify, Inc., suggesting platform-level enforcement pressure. Future monitoring points include whether originalc.co.uk implements third-party age-verification services and whether similar actions follow against other e-liquid retailers using comparable sales infrastructures. The letter warns that continued violations may trigger civil penalties, product seizure, or injunction proceedings.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER originalc.co.uk MARCS-CMS 739334 — October 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: RW2602440 Product: Tobacco Recipient: originalc.co.uk United Kingdom sales@originalc.co.uk Issuing Office: Center for Tobacco Products United States October 2, 2026 WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://originalc.co.uk and determined that e-liquid products listed there are offered for sale or distribution to consumers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. 1 Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901 of the FD&C Act (21 U.S.C. § 387a) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act. Under section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)), it is unlawful for any retailer 2 to sell a tobacco product to any person younger than 21 years of age. 3 This includes tobacco products containing nicotine from any source including cigarettes, smokeless tobacco, cigars, e-cigarettes, and nicotine pouches. Tobacco Product Sold by a Retailer to an Individual Under the Age of 21 is Misbranded Under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed by any retailer to a person younger than 21 years of age in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). FDA has determined that your Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg e-liquid product is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age. Specifically, during FDA’s investigation of https://originalc.co.uk, a person younger than 21 years of age purchased the Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg e-liquid product from your website. Conclusion and Requested Actions It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and/or injunction. Please note that tobac…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Tobacco / ENDS warning letter?
- Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has originalc.co.uk had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for originalc.co.uk as of 2026-10-13. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: originalc.co.uk (2026-10-02) — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-originalc-co-uk-2026-10-02-tobacco
"Warning Letter Record: originalc.co.uk (2026-10-02) — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-originalc-co-uk-2026-10-02-tobacco.
Argus HQ Research. "Warning Letter Record: originalc.co.uk (2026-10-02) — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Digital Empire Holdings LLC. Accessed October 15, 2026. https://argushq.ai/fda/warning-letter/fda-wl-originalc-co-uk-2026-10-02-tobacco.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_originalc_co_uk_2026_10_02_tobacco_2026,
title = {Warning Letter Record: originalc.co.uk (2026-10-02) — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-originalc-co-uk-2026-10-02-tobacco},
note = {Accessed: October 15, 2026}
}